Cheng Wang1, Xiaochun Xu1, Sassan Hodge1, Eunice Y Chen2, P Jack Hoopes1,2, Kenneth M Tichauer3, Kimberley S Samkoe4,5. 1. Thayer School of Engineering, Dartmouth College, Hanover, NH, USA. 2. Geisel School of Medicine, Dartmouth College, Hanover, NH, USA. 3. Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, USA. 4. Thayer School of Engineering, Dartmouth College, Hanover, NH, USA. Kimberley.S.Samkoe@dartmouth.edu. 5. Geisel School of Medicine, Dartmouth College, Hanover, NH, USA. Kimberley.S.Samkoe@dartmouth.edu.
Abstract
PURPOSE: Non-specific uptake and retention of molecular targeted agents and heterogeneous tissue optical properties diminish the ability to differentiate between tumor and normal tissues using molecular targeted fluorescent agents. Paired-agent imaging (PAI) can increase the diagnostic ability to detect tumor tissue by mitigating these non-specific effects and providing true molecular contrast by co-administration of an untargeted control imaging agent with a targeted agent. This study evaluates the suitability of available clinically translatable untargeted agents for the translation of PAI in fluorescence-guided surgery using an affibody-based targeted imaging agent (ABY-029). EXPERIMENTAL: DESIGN: Three untargeted agents that fluoresce near 700 nm and exhibit good clinical safety profiles (methylene blue, IRDye 700DX, and IRDye 680LT) were tested in combination with the clinically tested IRDye 800CW-labeled anti-epidermal growth factor receptor (EGFR) affibody molecule, ABY-029 (eIND 122,681). Properties of the untargeted agent important for human use and integrity of PAI were tested: (1) plasma protein binding; (2) fluorescence signal linearity in in vitro whole blood dilution; (3) in vivo pharmacokinetic matching to targeted agent in negative control tissue; and (4) in vivo diagnostic accuracy of PAI vs single agent imaging (SAI) of ABY-029 alone in orthotopic oral head and neck squamous cell carcinomas. RESULTS: IRDye 680LT outperformed IRDye 700DX and methylene blue with the highest signal linearity (R2 = 0.9998 ± 0.0002, 0.9995 ± 0.0004, 0.91 ± 0.02, respectively), the highest fluorescence yield in whole blood at 1 μM (104.42 ± 0.05, 103.68 ± 0.09, 101.9 ± 0.2, respectively), and the most closely matched ABY-029 pharmacokinetics in EGFR-negative tissues (binding potential error percentage = 0.31% ± 0.37%, 10.25% ± 1.30%, and 8.10% ± 5.37%, respectively). The diagnostic ability of PAI with ABY-029 and IRDye 680LT outperformed conventional SAI with an area-under-the-receiver-operating-characteristic curve (AUC) value of 0.964 vs. 0.854, and 0.978 vs. 0.925 in the Odyssey scanning system and Pearl wide field imaging system, respectively. CONCLUSION: PAI is a highly promising methodology for increasing detection of tumors in fluorescence-guided surgery. Although not yet clinically approved, IRDye 680LT demonstrates promise as an untargeted agent when paired with ABY-029. The clinical translation of PAI to maximize tumor excision, while minimizing normal tissue removal, could improve both patient survival and life quality.
PURPOSE: Non-specific uptake and retention of molecular targeted agents and heterogeneous tissue optical properties diminish the ability to differentiate between tumor and normal tissues using molecular targeted fluorescent agents. Paired-agent imaging (PAI) can increase the diagnostic ability to detect tumor tissue by mitigating these non-specific effects and providing true molecular contrast by co-administration of an untargeted control imaging agent with a targeted agent. This study evaluates the suitability of available clinically translatable untargeted agents for the translation of PAI in fluorescence-guided surgery using an affibody-based targeted imaging agent (ABY-029). EXPERIMENTAL: DESIGN: Three untargeted agents that fluoresce near 700 nm and exhibit good clinical safety profiles (methylene blue, IRDye 700DX, and IRDye 680LT) were tested in combination with the clinically tested IRDye 800CW-labeled anti-epidermal growth factor receptor (EGFR) affibody molecule, ABY-029 (eIND 122,681). Properties of the untargeted agent important for human use and integrity of PAI were tested: (1) plasma protein binding; (2) fluorescence signal linearity in in vitro whole blood dilution; (3) in vivo pharmacokinetic matching to targeted agent in negative control tissue; and (4) in vivo diagnostic accuracy of PAI vs single agent imaging (SAI) of ABY-029 alone in orthotopic oral head and neck squamous cell carcinomas. RESULTS: IRDye 680LT outperformed IRDye 700DX and methylene blue with the highest signal linearity (R2 = 0.9998 ± 0.0002, 0.9995 ± 0.0004, 0.91 ± 0.02, respectively), the highest fluorescence yield in whole blood at 1 μM (104.42 ± 0.05, 103.68 ± 0.09, 101.9 ± 0.2, respectively), and the most closely matched ABY-029 pharmacokinetics in EGFR-negative tissues (binding potential error percentage = 0.31% ± 0.37%, 10.25% ± 1.30%, and 8.10% ± 5.37%, respectively). The diagnostic ability of PAI with ABY-029 and IRDye 680LT outperformed conventional SAI with an area-under-the-receiver-operating-characteristic curve (AUC) value of 0.964 vs. 0.854, and 0.978 vs. 0.925 in the Odyssey scanning system and Pearl wide field imaging system, respectively. CONCLUSION: PAI is a highly promising methodology for increasing detection of tumors in fluorescence-guided surgery. Although not yet clinically approved, IRDye 680LT demonstrates promise as an untargeted agent when paired with ABY-029. The clinical translation of PAI to maximize tumor excision, while minimizing normal tissue removal, could improve both patient survival and life quality.
Authors: Janet E Dancey; Kevin K Dobbin; Susan Groshen; J Milburn Jessup; Andrew H Hruszkewycz; Maria Koehler; Ralph Parchment; Mark J Ratain; Lalitha K Shankar; Walter M Stadler; Lawrence D True; Amy Gravell; Michael R Grever Journal: Clin Cancer Res Date: 2010-03-09 Impact factor: 12.531
Authors: Kimberley S Samkoe; Jason R Gunn; Kayla Marra; Sally M Hull; Karen L Moodie; Joachim Feldwisch; Theresa V Strong; Daniel R Draney; P Jack Hoopes; David W Roberts; Keith Paulsen; Brian W Pogue Journal: Mol Imaging Biol Date: 2017-08 Impact factor: 3.488
Authors: Naoki Nishio; Nynke S van den Berg; Stan van Keulen; Brock A Martin; Shayan Fakurnejad; Quan Zhou; Guolan Lu; Stefania U Chirita; Michael J Kaplan; Vasu Divi; Alexander D Colevas; Eben L Rosenthal Journal: Mol Imaging Biol Date: 2020-02 Impact factor: 3.488
Authors: Cynthia L Schreiber; Canjia Zhai; Janel M Dempsey; Hannah H McGarraugh; Braden P Matthews; Caroline R Christmann; Bradley D Smith Journal: Bioconjug Chem Date: 2019-12-06 Impact factor: 4.774
Authors: Stan van Keulen; Naoki Nishio; Shayan Fakurnejad; Andrew Birkeland; Brock A Martin; Guolan Lu; Quan Zhou; Stefania U Chirita; Tymour Forouzanfar; A Dimitrios Colevas; Nynke S van den Berg; Eben L Rosenthal Journal: J Nucl Med Date: 2019-02-07 Impact factor: 10.057
Authors: Rebecca W Gao; Nutte Teraphongphom; Esther de Boer; Nynke S van den Berg; Vasu Divi; Michael J Kaplan; Nicholas J Oberhelman; Steven S Hong; Elissa Capes; A Dimitrios Colevas; Jason M Warram; Eben L Rosenthal Journal: Theranostics Date: 2018-03-28 Impact factor: 11.556